Apyx Medical Corp 8K

Apyx Medical Corporation reported stronger second-quarter 2026 results with double-digit revenue growth led by its Surgical Aesthetics segment, improved losses, expanded FDA clearance and initial AYON power liposuction launch, while reaffirming full-year 2026 guidance.

On August 6, 2026, Apyx Medical Corporation reported its financial results for the quarter ended June 30, 2026, announcing a 22% year-over-year increase in total revenue to $13.9 million driven by 28% growth in its Surgical Aesthetics segment, a reduced net loss attributable to stockholders of $3.2 million and improved adjusted EBITDA loss of $0.7 million, alongside expanded FDA 510(k) clearance and limited commercial launch of a reusable power liposuction handpiece for its AYON Body Contouring System, publication of supportive clinical data for Renuvion and Avéli combination treatments, and reaffirmation of its full-year 2026 revenue guidance of $59.0–$60.0 million and operating expense cap below $45.0 million.

Filing Facts

CIK

719135

Ticker

-

Form

8K

Source Type

sec

Accession

0001437749-26-026262

Alert Tier

6